Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04795869
Title Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Northwestern University

peripheral T-cell lymphoma

nasal type extranodal NK/T-cell lymphoma

angioimmunoblastic T-cell lymphoma


Brentuximab vedotin + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.